Last reviewed · How we verify

NCT04931004

Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

Completed EARLY_PHASE1 Last updated 30 January 2026
What this trial tests

EARLY_PHASE1 trial testing Mouthwash Product in Covid19 in 34 participants. Completed in 31 December 2022.

Timeline
21 July 2021
Primary endpoint
24 May 2022
31 December 2022

Quick facts

Lead sponsorRutgers, The State University of New Jersey
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposeprevention
Enrollment34
Start date21 July 2021
Primary completion24 May 2022
Estimated completion31 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rutgers, The State University of New Jersey

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, cross-sectional study evaluating the effect of commercially available mouthwashes on expelled/exhaled SARS-CoV-2 viral load using face mask sampling.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Mouthwash Product

Trials testing the same drug.

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Rutgers, The State University of New Jersey trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04931004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing